Teva's New Schizophrenia Drug Approval Boosts Price Target to $50

Following the FDA's approval of Teva Pharmaceutical Industries' new schizophrenia drug, Leader Capital Markets has raised its price target for the company's stock to $50, maintaining a buy recommendation. This target reflects a potential 22% upside from its previous closing price of $41.10. The upgrade is attributed to advancements in Teva's innovative drug development, improved business operations, and a strengthened balance sheet.

The FDA's approval on Friday was for WELTRUZA, a new monthly injection for schizophrenia treatment. Analyst Sabina Levy of Leader highlighted that this approval significantly reduces regulatory risk and enhances the outlook for Teva's innovative drug segment in the coming years. However, she noted that the next challenge is commercial: patient adoption, market penetration speed, and insurance coverage.

WELTRUZA, an subcutaneous injection of olanzapine, offers advantages over Eli Lilly's older injection, including no requirement for three hours of medical supervision post-injection and no need for loading doses or concurrent oral medication. Leader views the absence of mandatory monitoring as a major commercial advantage, simplifying treatment and removing a previous barrier to olanzapine injection use. Successful commercial launch, however, still depends on securing insurance coverage and hospital formulary inclusion.

Teva estimates that approximately 1.5 million of the 2.2 million schizophrenia patients in the U.S. are on medication, with about 300,000 currently using olanzapine pills, representing the primary target audience for WELTRUZA. The current market share for long-acting injections is 13-14%. Teva's CEO, Richard Francis, reiterated a combined annual sales target of $1.5 to $2 billion for WELTRUZA and UZEDY, another long-acting schizophrenia drug. Leader suggests that a favorable regulatory environment and a successful commercial strategy could lead to even higher revenues in the medium to long term.

Teva can leverage its existing sales infrastructure, as about 80% of the sales team covering UZEDY also targets relevant physicians for WELTRUZA, potentially limiting additional expenses. However, significant revenue contribution from WELTRUZA is not expected until the second half of 2027, with limited impact on 2026 results due to gradual insurance coverage expansion, projected to reach about 85% by the end of the first year post-launch. Medicaid program variations across U.S. states may also prolong coverage approval processes.

Looking ahead to its third-quarter earnings report on November 3rd, Leader's consensus estimates for Teva are $4.25 billion in revenue, $1.35 billion in adjusted EBITDA, and $0.72 earnings per share. Teva projects 2026 revenues between $16.5 and $16.85 billion. The company anticipates improved profitability in the second half of the year due to a more favorable product mix and cost savings from its efficiency program. A key focus for the upcoming report will be the performance of AUSTEDO, a major revenue driver for movement disorders, which is projected to generate $2.45 to $2.6 billion in sales this year, despite potential inventory and pricing adjustments impacting the second half.